First Quarter Financial Results and Operational Progress May 4, 2023 2 Developing Next Generation Programmed T Cell Therapies Disclaimer These slides contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements i ...

Exhibit 99.1 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS | --- | --- | |--------------------------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022 | 2 | | Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months Ended | | | March 31, 2023 and 2022 (Unaudited) | 3 | | Condensed Consolid ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2022 Earnings Conference Call March 7, 2023 8:30 AM ET Company Participants Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Julia Wilson - Consilium Strategic Advisors Conference Call Participants Gil Blum - Needham & Co. Mara Goldstein - Mizuho Group Matthew Phipps - William Blair Kelly Shi - Jefferies James Shin - Wells Fargo Sebastiaan van der Schoot - Van Lanschot Kempen Karina Rabayeva - Truist Securities Operator Ladies and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) o REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to OR o SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Olivia Manser - Director, Investor Relations Christian Itin - Chief Executive Officer Lucinda Crabtree - Chief Financial Officer Conference Call Participants Mara Goldstein - Mizuho Matthew Phipps - William Blair James Shin - Wells Fargo Securities Gil Blum - Needham & Company Operator Hello ladies and gentlemen and welcome to the Autolus Therapeutics Third Quarter 2022 Financial Results ...

Autolus Therapeutics plc (NASDAQ:AUTL) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Olivia Manser - Director, IR Christian Itin - CEO Lucinda Crabtree - CFO Conference Call Participants Mara Goldstein - Mizuho Rob Andrews - William Blair Bill Jahangiri - Truist Gil Blum - Needham & Company Kelly Shi - Jefferies Chuan Hong - JPMorgan Operator Hello, ladies and gentlemen, and welcome to the Autolus Therapeutics Second Quarter 2022 Financial Results Conference Call. As a remi ...

Exhibit 1 Registered Number 11185179 (England & Wales) Annual Report and Accounts for the year ended 31 December 2020 for Autolus Therapeutics pie AUTOLUS THERAPEUTICS PLC Company Information 3 Strategic Report 4 Directors' Report 11 Directors' Remuneration Report 18 Independent Auditor's Report to the Members of Autolus Therapeutics plc 43 Consolidated Income Statement for the 12 months ended 31 December 2020 51 Consolidated Balance Sheet 52 Consolidated Cash Flow Statement 53 Consolidated Statement of Cha ...